Enzyme Inhibitors | sciencenewsnet.in

Breaking News

Climate Change: Rising Temperatures May Impact Groundwater Quality

Eyesight from a 3D Printer

Advancing Image Generation: Latest AI Model Enhances Precision and Diversity in Text-to-Image Creation

Motivated to disagree: What can be learned about rapid polarization from the Israeli judicial reform?

Expert available: Fourth human case of bird flu confirmed in the U.S.

Not So Selfish After All: Viruses Use Freeloading Genes as Weapons

Tomato timekeeper: NF-YA3b gene’s role in flowering time revealed

Marital status and happiness during the COVID-19 pandemic

Stepfamily variation in parent–child relationship quality in later life

Adult sibling relationships: The impact of cohabitation, marriage, separation, and childbearing

05 Jul, 2024

Either ACEi or ARB therapy protect against kidney failure in those with advanced CKD

July 1, 2024 sarah JonasResearch Results

A systematic review and retrospective individual participant-level meta-analysis of 18 trials comprised of more than 1,700 participants found that initiating treatment with an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB) protects against kidney failure in patients with advanced chronic kidney disease (CKD).